Ptc Therapeutics (PTCT) Invested Capital (2012 - 2026)

Ptc Therapeutics' Invested Capital history runs 12 years deep, the most recent figure standing at $305.0 million for Q1 2026.

• On a quarterly basis, Invested Capital rose 1515.68% year-over-year to $305.0 million in Q1 2026; TTM through Mar 2026 was $346.7 million, a 371.53% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, down 67.7% from the prior year.
• Invested Capital improved to $305.0 million in Q1 2026 per PTCT's latest filing, from $6.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $305.0 million in Q1 2026 and bottomed at $6.0 million in Q4 2025.
• The 5-year median for Invested Capital is $19.2 million (2025), against an average of $38.2 million.
• Across the five-year window, Invested Capital tumbled 72.02% in 2023 and surged 1515.68% in 2026, its largest moves.
• Year by year, Invested Capital stood at $72.1 million in 2022, then tumbled by 72.02% to $20.2 million in 2023, then retreated by 7.98% to $18.6 million in 2024, then sank by 67.7% to $6.0 million in 2025, then jumped by 4984.02% to $305.0 million in 2026.
• Per Business Quant, the three latest PTCT Invested Capital figures stand at $305.0 million (Q1 2026), $6.0 million (Q4 2025), and $16.5 million (Q3 2025).